Compare Coupang Inc (CPNG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs TG Therapeutics Inc — how do they compare? Coupang Inc trades at $15.82 (market cap $27.70B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Coupang Inc is far larger — about 3.4× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and TG Therapeutics Inc for 16 Days on average.
| CPNG | TGTX | |
|---|---|---|
Market Cap | $27.70B | $8.16B |
Volume | 27,703,608 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $59.06 |
52-Week Low | $13.75 | $26.94 |
Typical Hold Time | 55 Days | 16 Days |
Enterprise Value | $27.22B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $15.41, up 4.05% today, with a bullish technical signal and strong analyst support. Revenue grew to $34.53B in 2025, though recent quarterly EPS misses and a negative net income margin of -2.16% highlight profitability challenges. The stock is supported by positive cash flow from operations of $1.77B and a dominant e-commerce position in South Korea, but faces competitive pressure and a projected net loss in 2026.
The outlook balances high growth potential against near-term earnings volatility. Investment appeal lies in market dominance and analyst consensus price target of $25.25, implying significant upside, but risks include intense competition, regulatory scrutiny from U.S.-South Korea trade tensions (CNBC, 2026-08-31), and execution hurdles in expanding logistics networks.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
